Your browser doesn't support javascript.
loading
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.
Bastida, G; Marín-Jiménez, I; Forés, A; García-Planella, E; Argüelles-Arias, F; Tagarro, I; Fernandez-Nistal, A; Montoto, C; Aparicio, J; Aguas, M; Santos-Fernández, J; Boscá-Watts, M M; Ferreiro-Iglesias, R; Merino, O; Aldeguer, X; Cortés, X; Sicilia, B; Mesonero, F; Barreiro-de Acosta, M.
Affiliation
  • Bastida G; Department of Gastroenterology, Hospital La Fe, Valencia, Spain. Electronic address: guille.bastida@gmail.com.
  • Marín-Jiménez I; Department of Gastroenterology, Hospital Gregorio Marañón and Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Forés A; Hospital General Universitario de Castellón, Castellón, Spain.
  • García-Planella E; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Argüelles-Arias F; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Tagarro I; Takeda Farmacéutica España S.A., Madrid, Spain.
  • Fernandez-Nistal A; Takeda Farmacéutica España S.A., Madrid, Spain.
  • Montoto C; Takeda Farmacéutica España S.A., Madrid, Spain.
  • Aparicio J; Takeda Farmacéutica España S.A., Madrid, Spain.
  • Aguas M; Department of Gastroenterology, Hospital La Fe, Valencia, Spain.
  • Santos-Fernández J; Department of Gastroenterology, Hospital Universitario Río Hortega, Valladolid, Spain.
  • Boscá-Watts MM; IBD Unit, Gastroenterology Department of the University Clinic Hospital of Valencia, Valencia, Spain.
  • Ferreiro-Iglesias R; Department of Gastroenterology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
  • Merino O; Department of Gastroenterology, Hospital Universitario Cruces, Bilbao, Spain.
  • Aldeguer X; Department of Gastroenterology, Hospital Dr Josep Trueta, Girona, Spain.
  • Cortés X; IBD Unit, Gastroenterology Section, Internal Medicine Hospital of Sagunto, Sagunto, Spain; University of Cardenal Herrera-CEU, Castellón, Spain.
  • Sicilia B; Hospital Universitario de Burgos, Burgos, Spain.
  • Mesonero F; Gastroenterology Department, Hospital Ramón y Cajal, Madrid, Spain.
  • Barreiro-de Acosta M; Department of Gastroenterology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Dig Liver Dis ; 54(1): 76-83, 2022 Jan.
Article in En | MEDLINE | ID: mdl-34244110
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colitis, Ulcerative / Crohn Disease / Adalimumab / Infliximab / Tumor Necrosis Factor Inhibitors Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Dig Liver Dis Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colitis, Ulcerative / Crohn Disease / Adalimumab / Infliximab / Tumor Necrosis Factor Inhibitors Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Dig Liver Dis Year: 2022 Document type: Article